Atricure Form 4 Filings

AtriCure, Inc. (ATRC) reported that Chief Legal Officer Karl S. Dahlquist sold 9,370 shares of common stock on 2026-08-24 in a sale classified as an open market or private transaction. The weighted average sales price was approximately $48.89 per share, with trades executed between $48.88 and $48.89. Following this transaction, Dahlquist directly holds 87,319 AtriCure common shares.

AtriCure, Inc. director Karen Prange reported a sale of 3,564 shares of Common Stock on 2026-08-05 at $38.80 per share in a sale in open market or private transaction. Following this transaction, she directly holds 22,809 AtriCure shares.

AtriCure, Inc. director Maggie Yuen reported selling 3,500 shares of Common Stock on August 5, 2026. The shares were sold in multiple trades at prices between $38.37 and $38.43, for a weighted average price of $38.42 per share. Following this transaction, she holds 14,015 shares directly. The Rule 10b5-1 trading plan checkbox was not selected.

Michael H. Carrel, President, CEO, & Director of AtriCure, Inc., reported bona fide gifts of 4,700 shares of common stock on July 30, 2026. These included 700 shares to a parent and 4,000 shares as a charitable gift, with no consideration received. He also reports indirect holdings of 14,310 shares held by his children, 2,950 shares held by a parent, and 1,000 shares held by a sibling, for which he disclaims beneficial ownership except for his pecuniary interest.

AtriCure Chief Scientific Officer Vinayak Doraiswamy sold 6,000 shares of common stock on July 28, 2026 in a sale classified as an open-market or private transaction at a weighted average price of $38.88 per share, with individual trades between $38.87 and $38.92. After this transaction, he directly holds 86,511 shares of AtriCure common stock.

AtriCure director Sven Wehrwein exercised 25,000 non-qualified stock options at an exercise price of $19.95 per share on July 28, 2026, converting them into 25,000 shares of common stock. The same day, he sold 25,000 shares at a weighted average price of $37.84 per share in multiple trades between $37.73 and $39.04. Following the exercise, no options remain outstanding under this specific grant.

AtriCure, Inc. reported that Chief Marketing & Strategy Officer Justin J. Noznesky sold 6,182 shares of common stock on July 29, 2026. The shares were sold at a weighted average price of $38.80 per share, in multiple trades ranging from $38.62 to $39.28. Following this transaction, Noznesky directly holds 100,219 shares of AtriCure common stock.

AtriCure, Inc. President and CEO Michael H. Carrel reported a new share acquisition through an employee purchase program. On June 30, 2026, he acquired 636 shares of common stock directly at an effective price of $23.78 per share under AtriCure’s 2018 Employee Stock Purchase Plan.

These shares were purchased at 85% of the $27.98 closing price on June 30, 2026, as provided by the plan. After this transaction, Carrel directly holds 779,134 common shares. Additional indirect holdings are reported as shares held by his sibling, parents, and children, for which he disclaims beneficial ownership except for any pecuniary interest.

Chief Scientific Officer Doraiswamy Vinayak acquired additional AtriCure, Inc. common stock through an employee purchase program. On June 30, 2026, he obtained 636 shares of Common Stock pursuant to the company’s 2018 Employee Stock Purchase Plan at $23.78 per share, a price based on 85% of the $27.98 closing price that day. Following this transaction, he directly holds 92,511 common shares, reflecting a small, routine compensation-related acquisition rather than an open-market trade.

AtriCure, Inc. reported that Chief Legal Officer Karl S. Dahlquist acquired 636 shares of common stock on June 30, 2026 through the company’s 2018 Employee Stock Purchase Plan. The shares were acquired at approximately $23.78 per share, based on 85% of the $27.98 closing price on that date, bringing his direct holdings to 96,689 shares.

AtriCure, Inc. Chief Operating Officer Douglas J. Seith acquired 527 shares of common stock through the company’s 2018 Employee Stock Purchase Plan for the period ended June 30, 2026. The shares were purchased at $23.78 each, bringing his direct holdings to 229,867 shares.

AtriCure, Inc. Chief Technical Officer Salvatore Privitera acquired additional company stock through an employee plan. On June 30, 2026, he received 636 shares of common stock, bringing his direct holdings to 158,684 shares. The shares were bought under AtriCure's 2018 Employee Stock Purchase Plan for the period ended June 30, 2026.

According to the plan terms, these shares were purchased at 85% of the June 30, 2026 closing price of $27.98 per share, resulting in an effective purchase price of $23.78 per share. This is a routine compensation-related acquisition rather than an open-market trade.

AtriCure, Inc. director Karen Prange reported an open-market sale of 3,000 shares of common stock on May 20, 2026 at a weighted average price of $28.65 per share. After this transaction, she directly holds 26,373 shares of AtriCure common stock.

The sale was executed in multiple trades within a price range of $28.60 to $28.76 per share, with the reported price reflecting the weighted average sales price.

AtriCure, Inc. director Karen Prange reported an equity compensation grant of common stock. She acquired 6,144 shares of AtriCure common stock at no cash cost as a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan, which will vest on the one-year anniversary of the grant date. Following this award, she holds 29,373 common shares directly.

Telman Deborah H reported acquisition or exercise transactions in this Form 4 filing.

AtriCure, Inc. director Deborah H. Telman received a grant of 6,144 shares of Common Stock as a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest on the one-year anniversary of the grant date. Following this award, she holds 28,328 shares of AtriCure common stock directly.

AtriCure, Inc. director Maggie Yuen reported receiving a grant of common stock as equity compensation. She was awarded 6,144 shares of Common Stock on May 18, 2026 at a stated price of $0.00 per share under the AtriCure, Inc. 2023 Stock Incentive Plan.

The award is structured as restricted stock and will vest on the one-year anniversary of the grant date. Following this grant, Yuen directly holds 17,515 shares of AtriCure common stock. This filing reflects a compensation-related acquisition rather than an open-market purchase.

Nachman Shlomo reported acquisition or exercise transactions in this Form 4 filing.

AtriCure director Nachman Shlomo received a grant of 6,144 shares of AtriCure, Inc. common stock as a Restricted Stock Award under the company’s 2023 Stock Incentive Plan. The award was granted at no cash cost and will fully vest on the one-year anniversary of the grant date. Following this equity grant, Shlomo directly owns 24,655 shares of AtriCure common stock.

AtriCure, Inc. director Kristine B. Johnson reported receiving a grant of common stock as equity compensation. She acquired 6,144 shares of Common Stock on May 18, 2026 at a stated price of $0.00 per share under the AtriCure, Inc. 2023 Stock Incentive Plan.

The award is structured as a Restricted Stock Award, with all 6,144 shares scheduled to vest on the one-year anniversary of the grant date. Following this grant, Johnson directly holds a total of 55,954 shares of AtriCure common stock, reflecting her updated ownership position as reported.

GROVES REGINA E reported acquisition or exercise transactions in this Form 4 filing.

AtriCure, Inc. director Regina E. Groves received a grant of 6,144 shares of Common Stock as a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The footnote states these shares will vest on the one-year anniversary of the grant date. After this equity award, Groves directly holds 39,859 shares of AtriCure common stock.

WEHRWEIN SVEN reported acquisition or exercise transactions in this Form 4 filing.

AtriCure, Inc. director Sven Wehrwein received a grant of 6,144 shares of common stock as equity compensation. The award was made at a price of $0.00 per share under the AtriCure, Inc. 2023 Stock Incentive Plan and is structured as a Restricted Stock Award. According to the terms, these shares will vest on the one-year anniversary of the grant date. Following this grant, Wehrwein directly holds a total of 40,518 shares of AtriCure common stock.

WHITE ROBERT S. reported acquisition or exercise transactions in this Form 4 filing.

AtriCure, Inc. director Robert S. White received a grant of 6,144 shares of common stock as a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award has no purchase price and will vest in full on the one-year anniversary of the grant date.

After this grant, White directly holds a total of 128,318 shares of AtriCure common stock, reflecting routine equity-based compensation rather than an open-market purchase or sale.

AtriCure, Inc. Chief Scientific Officer Doraiswamy Vinayak sold 5,000 shares of common stock in an open-market transaction at a price of $28.13 per share. After this sale on May 15, he directly holds 91,875 AtriCure common shares.

AtriCure, Inc. Chief Scientific Officer Doraiswamy Vinayak reported an open-market sale of 5,000 shares of common stock. The shares were sold at a weighted average price of $29.83 per share, in multiple trades executed between $29.79 and $29.92. Following this transaction, he directly holds 96,875 shares of AtriCure common stock.

AtriCure, Inc. director Robert S. White exercised non-qualified stock options for 10,000 shares at $14.99 per share. These options were originally granted on May 25, 2016 and vested over four years. Following the exercise, he directly holds 122,174 shares of AtriCure common stock.

AtriCure, Inc. President, CEO, and Director Michael H. Carrel reported bona fide gifts totaling 6,000 shares of AtriCure common stock on March 6, 2026, consisting of separate transfers of 5,000 shares and 1,000 shares. No consideration was received for these gifts to his children and sibling, and his directly owned stake was reported as 778,498 shares following the gifts. He also reported indirect holdings held by his children, parents, and sibling, and disclaimed beneficial ownership of those indirect holdings except for his pecuniary interest.

AtriCure, Inc. President and CEO Michael H. Carrel reported equity compensation and related tax withholding transactions in AtriCure common stock. On March 1, 2026, he acquired 68,618 shares through a restricted stock award under the AtriCure, Inc. 2023 Stock Incentive Plan, with one third of the shares vesting on each of the first, second, and third anniversaries of the grant date.

He also acquired 101,280 shares upon the vesting and release of a performance share award under the same 2023 plan, after the company performance goals and required service period were met. To cover tax withholding obligations from vesting awards, he transferred 72,777 shares back to the company at $31.26 per share, characterized as a tax-withholding disposition. After these direct transactions, he directly held 784,498 shares of common stock.

In addition, Form 4 reflects 9,310 shares held indirectly by his children and 2,250 shares held indirectly by his parents. A footnote states he disclaims beneficial ownership of these indirectly held securities, except to the extent of his pecuniary interest.

AtriCure, Inc. Chief Marketing & Strategy Officer Justin J. Noznesky reported equity compensation and related tax withholding in company stock. He acquired 27,991 shares through a new restricted stock award and 15,198 shares from a performance share award that vested after meeting company performance and service requirements. To cover tax obligations on vested awards, he transferred 15,586 shares back to the company at a price of $31.26 per share, leaving him with 106,401 shares of common stock held directly.

AtriCure, Inc. Chief Technical Officer Salvatore Privitera reported equity compensation activity involving company common stock. He acquired 30,390 shares on March 1, 2026 through a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan, with one third of the shares vesting on each of the first, second, and third anniversaries of the grant date. He also acquired 15,198 shares on the same date from the vesting and release of a Performance Share Award under the same plan after company performance goals and service requirements were met. To cover tax withholding obligations related to vesting and release of prior awards, he transferred 13,127 shares back to the company at $31.26 per share, and directly owned 158,048 shares after these transactions.

AtriCure, Inc. Chief Scientific Officer Doraiswamy Vinayak reported equity awards and related tax withholding transactions in company common stock. He acquired 30,390 shares through a restricted stock award under the 2023 Stock Incentive Plan, with one third vesting on each of the first, second, and third anniversaries of the grant date. He also acquired 15,198 shares from the vesting and release of a performance share award after company performance goals and service requirements were met. To cover tax obligations from earlier restricted or performance share vesting, he transferred 15,585 shares back to AtriCure at a price of $31.26 per share.

AtriCure, Inc. reported equity award activity for Chief Financial Officer Angela L. Wirick. On March 1, 2026, she acquired 39,987 shares of common stock through a restricted stock award under the 2023 Stock Incentive Plan, which will vest in three equal annual installments. She also acquired 23,101 shares from the vesting of a performance share award after company performance goals and service requirements were met. To cover tax withholding from these vestings, she disposed of 22,965 shares back to the company at $31.26 per share, leaving her with 204,893 directly owned shares of common stock.

AtriCure, Inc. Chief Operating Officer Douglas J. Seith reported equity compensation and related tax withholding in company stock. On March 1, 2026, he received 42,386 shares of common stock as a restricted stock award that vests in three equal annual installments. He also acquired 25,532 shares through the vesting and release of a performance share award after company performance goals and service requirements were met. To cover tax obligations from these vestings, he transferred 22,948 shares back to the company at $31.26 per share. Following these transactions, he directly owned 229,340 shares of AtriCure common stock.

AtriCure, Inc.’s Chief Legal Officer, Karl S. Dahlquist, reported equity compensation and related tax withholding transactions in company common stock. He acquired 27,991 shares through a restricted stock award and 15,198 shares through the vesting of a performance share award under the 2023 Stock Incentive Plan.

According to the filing, one third of the restricted stock will vest on each of the first, second, and third anniversaries of the grant date. The performance share award vested after company performance goals and service requirements were met.

Dahlquist also disposed of 15,687 shares at a price of $31.26 per share by transferring them back to the company to satisfy tax withholding obligations arising from the vesting and release of earlier restricted stock or performance share awards.

AtriCure, Inc. President, CEO, and Director Michael H. Carrel reported a charitable gift of 4,000 shares of AtriCure common stock on 12/10/2025. The transfer is coded as a gift and recorded at a price of $0, reflecting that no consideration was received for the donation. After this transaction, he beneficially owns 687,377 shares directly, with an additional 9,310 shares held by his children and 2,250 shares held by his parents, which he reports as indirect holdings while disclaiming beneficial ownership except for his pecuniary interest.

AtriCure, Inc. (ATRC) director reports option exercises and share sales. On 11/24/2025, the reporting person exercised 5,033 non-qualified stock options at $19.95 per share and sold 5,033 shares of common stock at a weighted average price of $37.32 per share. On 11/25/2025, they exercised an additional 4,967 options at $19.95 and sold 4,967 shares at $38.00 per share.

After these transactions, the director beneficially owned 34,374 shares of AtriCure common stock directly and held 25,000 non-qualified stock options. The options exercised on these dates were originally granted on November 11, 2016 and vest over four years, with 25% after one year and the remainder in monthly installments over the next three years.

AtriCure, Inc. (ATRC) reported an insider stock transaction by its Chief Marketing & Strategy Officer. On 11/26/2025, the officer sold 5,166 shares of AtriCure common stock in an open market transaction coded "S" for sale.

The reported sale price is a weighted average of $37.29 per share, with individual trades executed at prices ranging from $36.51 to $38.44 per share. After this transaction, the officer beneficially owns 78,798 shares of AtriCure common stock, held directly.

AtriCure, Inc. (ATRC) reported an insider share sale by a director. On 11/21/2025, the reporting person sold 3,000 shares of AtriCure common stock in an open-market transaction coded as a sale. The weighted average sale price was $35.72 per share, with individual trade prices ranging from $35.71 to $35.76.

Following this transaction, the director beneficially owns 11,371 AtriCure shares, held directly. The filing notes that detailed trade data for the individual prices and share amounts within the reported range will be provided upon request to the SEC staff, the issuer, or any security holder.

AtriCure, Inc. CEO and President Michael H. Carrel, who also serves as a director, reported a charitable gift of 6,000 shares of AtriCure common stock on 11/13/2025, according to a Form 4 filing. The transaction used code “G,” indicating a gift, and was reported at a price of $0, with the filing noting that no consideration was received for this transfer.

After the reported transaction, Carrel beneficially owns 691,377 shares of AtriCure common stock directly. The filing also lists 9,310 shares held indirectly through his children and 2,250 shares held indirectly through his parents, with a statement that he disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.

Insider sale by AtriCure officer: Justin J. Noznesky, Chief Marketing & Strategy Officer and director, sold 3,000 shares of AtriCure, Inc. (ATRC) common stock on 09/12/2025 at a weighted average price of $36.30 per share. After the transaction he beneficially owned 83,964 shares. The Form 4 discloses the sale price range ($36.28–$36.36) and states the reported price is a weighted average; the filer offers to provide detailed trade-by-trade information on request. The form is signed and dated 09/16/2025.